Payment overview · 2025
General Payments
$188.51
9 reported records · 8 companies
Healthcare provider profile · identity verified
Anthony Haeufgloeckner, DO
Allopathic & Osteopathic Physicians|Family Medicine · CANTON, OH · NPI 1285667782
Verified facts
What the public records show
CMS Open Payments records show Anthony Haeufgloeckner, DO received $188.51 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.56 | 19.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.85 | 17.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.95 | 13.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.80 | 12.1% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.11 | 10.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.69 | 9.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.65 | 8.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.90 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.51 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 72 |
| Omeprazole | Omeprazole | 176 | 47 |
| Montelukast Sodium | Montelukast Sodium | 165 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 38 |
| Lisinopril | Lisinopril | 144 | 43 |
| Metformin Hcl Er | Metformin Hcl | 133 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 38 |
| Gabapentin | Gabapentin | 132 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 40 |
| Losartan Potassium | Losartan Potassium | 122 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 29 |
| Furosemide | Furosemide | 118 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 28 |
| Sertraline Hcl | Sertraline Hcl | 105 | 28 |
| Tramadol Hcl | Tramadol Hcl | 98 | 19 |
| Valsartan | Valsartan | 98 | 26 |
| Irbesartan | Irbesartan | 90 | 19 |
| Potassium Chloride | Potassium Chloride | 86 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 27 |
| Alprazolam | Alprazolam | 62 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 26 |
| Jardiance | Empagliflozin | 59 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 14 |
| Allopurinol | Allopurinol | 58 | 21 |
| Ezetimibe | Ezetimibe | 58 | 15 |
| Simvastatin | Simvastatin | 58 | 14 |
| Eliquis | Apixaban | 57 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Spironolactone | Spironolactone | 57 | 15 |
| Metformin Hcl | Metformin Hcl | 55 | 16 |
| Azithromycin | Azithromycin | 51 | 42 |
| Carvedilol | Carvedilol | 51 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 51 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 11 |
| Trazodone Hcl | Trazodone Hcl | 48 | 18 |
| Donepezil Hcl | Donepezil Hcl | 47 | 11 |
| Glipizide Er | Glipizide | 46 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 12 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 40 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Atenolol | Atenolol | 38 | 11 |
| Famotidine | Famotidine | 38 | 15 |
| Naproxen | Naproxen | 38 | 15 |
| Amoxicillin | Amoxicillin | 37 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 13 |
| Meloxicam | Meloxicam | 37 | 13 |
| Celecoxib | Celecoxib | 36 | 13 |
| Finasteride | Finasteride | 36 | 14 |
| Prednisone | Prednisone | 36 | 23 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | suppressed |
| Cephalexin | Cephalexin | 32 | 29 |
| Methylprednisolone | Methylprednisolone | 32 | 29 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Bumetanide | Bumetanide | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.51 · 9 records | Novo Nordisk Inc | Auvelity, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, GOMEKLI, INSPIRE, Korlym, Ozempic, QULIPTA, ROTATEQ, UBRELVY, VAXELIS, VAXNEUVANCE, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error